Ver­tex-part­nered gene ther­a­py biotech Affinia scraps IPO plans

Affinia Ther­a­peu­tics has ditched its plans to go pub­lic in a rel­a­tive­ly closed-door mar­ket that has not fa­vored Nas­daq de­buts for the drug de­vel­op­ment in­dus­try …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER